(8S,13S,14S,17S)-5,10,17-Trihydroxy-13-methyl-17-prop-1-ynyl-1,2,4,5,6,7,8,10,12,13,14,15,16,17-tetradeca hydro-cyclopenta[a]phenanthren-3-one


Product Details

CAT No.# CS-O-16564
Category Impurities
Molecular Weight 344.44
Molecular Formula C21H28O4
Purity: >98
Synonyms: (8S,13S,14S,17S)-5,10,17-trihydroxy-13-methyl-17-(prop-1-yn-1-yl)-4,5,6,7,8,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one
Application Notes: Impurity in commercial preparations of Mifepristone.
Shipping: Free Shipping for worldwide on order above 2000 USD , Extra charges for Dry ice shipment 80$*
COA / MSDS:    View COA    MSDS    Enquire
The balance used are calibrated with weights traceable to National Standards NIST for accuracy
Related Results for '(8S,13S,14S,17S)-5,10,17-Trihydroxy-13-methyl-17-prop-1-ynyl-1,2,4,5,6,7,8,10,12,13,14,15,16,17-tetradeca hydro-cyclopenta[a]phenanthren-3-one'

- API Standards of Mifepristone
- Stable Isotopes of Mifepristone
- Metabolites of Mifepristone
- Impurities of Mifepristone
- Glucuronides of Mifepristone
- Intermediates of Mifepristone

PEOPLE ALSO SEARCHED FOR: 1. propan-2-yl-5-hydroxy-2-methyl-2-4-(3-nitrophenyl)-6-oxo-1,4,5,5-tetraahydropyridine-3-carboxylate
2. ([13C6]Leu5)-Ghrelin (human) (H-7252.1000)
3. Benidipine D7
4. Lauroside D
5. Triazolam 13C D3
6. Icatibant impurity 1
8. 0.1% TFA in Water ULC-MS
9. Metamizole EP Impurity C HCl
10. Silodosin Metabolite D4
11. Brivaracetam Carboxylic acid metabolite [UCB 42145]
12. Terbuthylazine D5
13. tibolone (848)
14. (Z)-Dimethylvinphos
15. Silodosin Metabolite
16. 2-Phenoxymethanesulfonanilide
17. Nimesulide EP Impurity A
18. Acetone HPLC
19. Nandrolone Decanoate EP impurity F
20. N-(4-Bromophenyl)-3-methyl-N-(m-tolyl)aniline

This page contains information about (8S,13S,14S,17S)-5,10,17-Trihydroxy-13-methyl-17-prop-1-ynyl-1,2,4,5,6,7,8,10,12,13,14,15,16,17-tetradeca hydro-cyclopenta[a]phenanthren-3-one Cas NA and its Impurities.
"Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk."